Search

everythinglearnresearchcommunity

for

Search:↓

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

The user experienced gradual hair thinning since 2021 and tried various treatments including topical minoxidil, rosemary oil, oral finasteride, oral minoxidil, RU58841, and oral dutasteride. They are considering switching to daily finasteride and adding topical dutasteride, tretinoin, and microneedling due to side effects from oral dutasteride.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The user is using a regimen of dutasteride, oral and topical minoxidil, Nutrafol, and keto shampoo for hair regrowth, with plans for a hair transplant at the one-year mark. Users suggest adjusting treatments due to scalp inflammation and discuss the potential addition of RU58841, while noting impressive results so far.

The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.

A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

The conversation discusses using Duodart (dutasteride + tamsulosin) for hair loss, with side effects like frequent urination and ejaculation issues leading to discontinuation. The user switched to German Avodart and experienced mood and erection side effects, considering adjusting the dosage to three times a week.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

The user is taking 1mg finasteride daily and RU58841 5% but still experiencing hair loss. They are considering adding topical finasteride or switching to dutasteride, and are not planning to use minoxidil until hair loss stabilizes.

The user is using oral minoxidil for hair loss and is considering trying Latisse on their hairline. They are also curious about the effects of latanoprost, caffeine, and melatonin topicals.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

. This user experienced positive results from using a combination of minoxidil and finasteride, with no reported side effects after two months. Others have also shared their experiences with both short-term and long-term use of finasteride.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

A user is using RU58841 and pyrilutamide for hair loss and is seeing their hairline return, but the process is slow. They also mention using finasteride and dutasteride, with finasteride causing reduced libido but no noticeable side effects from RU58841 or pyrilutamide.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

A 34-year-old woman has been using a topical solution of 5% Minoxidil and 0.1% Finasteride since January 2026 to address hair thinning caused by PCOS and poor nutrition. She reports ongoing hair shedding but has improved her diet with whole foods and supplements.

The user is using a hair loss treatment with finasteride 0.1%, minoxidil 5%, and tretinoin 0.01%, applied once daily at 1ml. They are questioning if a 60ml bottle used twice daily implies a higher recommended dose despite the same 5% minoxidil concentration.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

The user switched from finasteride to dutasteride and from oral to topical minoxidil, noticing better hair regrowth with the new regimen. They experienced no side effects from dutasteride and found topical minoxidil more effective than oral.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The post discusses a user's six-year progress with finasteride and a Follicular Unit Transplant (FUT) for hair loss. The user shared before and after photos in reverse order, leading to confusion, but overall, the community responded positively to the user's hair regrowth.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

A 48-year-old male from the Philippines shared his two-year progress using finasteride only for hair regrowth, experiencing significant improvement without minoxidil. He started with 0.5mg and increased to 1.25mg, later adjusting to every other day due to elevated liver enzymes, and reported 90% hair restoration.

A 40-year-old man experiencing male pattern baldness reports noticeable hair regrowth after 6 weeks of using finasteride 1 mg daily, topical minoxidil 5% twice a day, and ketoconazole shampoo twice a week. He has not experienced any side effects and plans to continue monitoring his progress.